-
2024-513356-15-00
5
2024-12-30
Acquired Blepharoptosis
-
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-507717-94-00
5
2024-12-06
Deep partial and full-thickness burns
-
2023-509482-20-00
4
2024-12-03
Solid Tumors
-
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2024-512423-36-00
5
2024-11-20
Undifferentiated pleomorphic sarcoma
-
2023-508996-35-00
4
2024-11-18
Rheumatoid Arthritis
-
2023-506757-38-00
1
2024-11-14
Advanced/metastatic solid tumors that are MTAP deficient.
-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2024-512707-40-00
4
2024-11-07
RELAPSING MULTIPLE SCLEROSIS
-
2023-509877-22-00
5
2024-10-30
severe von Willebrand Disease
-
2023-508805-26-00
1
2024-10-23
patients with active brain metastases, where the primary tumour has co
-
2023-504358-36-00
5
2024-10-17
multiple sclerosis
-
2023-505606-42-00
5
2024-10-15
Head and Neck Squamous Cell Carcinoma (HNSCC)
-
2024-512217-40-00
10
2024-10-11
Malignant Solid Tumors
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-507536-21-00
7
2024-10-04
Advanced Solid Tumors
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-510017-26-00
1
2024-10-02
Completely Resected Stage IIB, IIC, and III Melanoma
-
2023-510022-33-00
5
2024-10-02
HIV-1 infection
-
2023-504445-31-00
4
2024-09-19
Carcinoma, Head and Neck